Holly L Cranmer (Holly Cranmer)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 7

Top Topics

Chronic Myeloid Leukemia

Systematic Review

Decision Making

Top Venues

Applied health economics and health policy

Future oncology (London, England)

Heart (British Cardiac Society)

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Holly L Cranmer, Gemma Elizabeth Shields, Ash Bullement
An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology. Applied health economics and health policy (2023)
Gemma Elizabeth Shields, Aleix Rowlandson, Garima Dalal, Stuart Nickerson, Holly L Cranmer, Lora Capobianco, Patrick Joseph Doherty
Cost-effectiveness of home-based cardiac rehabilitation: a systematic review. Heart (British Cardiac Society) (2023)
Karen L Reckamp, Huamao Mark Lin, Holly L Cranmer, Yanyu Wu, Pingkuan Zhang, Stephen Kay, Laura J Walton, Junwu Shen, Sanjay Popat, D Ross Camidge
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L. Current medical research and opinion 38 (9) (2022)
Karen L Reckamp, Huamao Mark Lin, Holly L Cranmer, Yanyu Wu, Pingkuan Zhang, Laura J Walton, Stephen Kay, Allie Cichewicz, Binod Neupane, Kyle Fahrbach, Sanjay Popat, D Ross Camidge
Indirect comparisons of brigatinib and alectinib for front-line ALK -positive non-small-cell lung cancer. Future oncology (London, England) 18 (20) (2022)
Tanja Podkonjak, Holly L Cranmer, Julia J Scarisbrick, Grant McCarthy, Cameron Lilley, Lung-I Cheng
Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. Journal of comparative effectiveness research (2021)
Ash Bullement, Holly L Cranmer, Gemma Elizabeth Shields
A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments. Applied health economics and health policy 17 (6) (2020)
Holly L Cranmer, Gemma Elizabeth Shields, Ash Bullement
A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. Journal of medical economics 23 (10) (2020)